16/02/23 - WA-based biotechnology company Argenica Therapeutics has attracted a $1.2 million grant for work on a potential therapeutic drug for mild and moderate traumatic brain injury.
The novel therapeutic, ARG-007, is a neuroprotective peptide drug developed by researchers at the Perron Institute and The University of Western Australia and being further developed by Argenica.
“This drug, which is currently at the clinical trial stage as a treatment to reduce brain damage following ischaemic stroke, has been shown in preclinical research to have efficacy for some other neurological conditions,” said Perron Institute Head of Stroke Laboratory Research and Argenica Chief Scientific Officer Professor Bruno Meloni.
“This includes traumatic brain injury, with potential to minimise brain damage and reduce neuroinflammation when administered early.”
The recent funding, which will support work by Argenica and its project partners in building on existing preclinical data relating to reducing damage to brain cells in traumatic brain injury, has been awarded under the Federal Government’s Cooperative Research Centre Projects grant program.
It will contribute to a preclinical program of work on mild to moderate traumatic brain injury in collaboration with project partners Curtin University (through the Perron Institute), the University of Adelaide, Australian peptide manufacturer AusPep and Connectivity Traumatic Brain Injury Australia.
Professor Lindy Fitzgerald, who will lead the program of work to be undertaken at Curtin University and the Perron Institute, and postdoctoral researchers Dr Chidozie Anyaegbu and Dr Sarah Hellewell (Curtin University and Perron Institute) will work with Professor Fitzgerald to deliver the research program.
Argenica CEO and Managing Director, Dr Liz Dallimore, said the company would work with the Department of Industry, Science and Resources and project partners to finalise the grant agreements.
Prof Lindy Fitzgerald in the Perron Institute lab.
Tennille Kroemer, Communications Manager, Perron Institute
Mobile: 0426 044 223